Rosa Biotech accelerates NASH pre-clinical trial in liver disease
The company, spun out from the University of Bristol in 2019, is initially targeting the early identification of non-alcoholic fatty liver disease (NAFL) which, if left untreated, can develop into steatohepatitis (NASH) leading to liver failure. The number of global NASH cases has grown significantly over the last 30 years and this trend is expected … [Read more…]